1. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database
- Author
-
Francis Mégraud, Nicholas Moore, Régis Lassalle, Magali Rouyer, Cécile Droz-Perroteau, François Tison, Bertrand Diquet, Abdelilah Abouelfath, E. Guiard, Patrick Blin, and Frank Zerbib
- Subjects
medicine.medical_specialty ,Index date ,medicine.drug_class ,Proton-pump inhibitor ,030226 pharmacology & pharmacy ,Helicobacter Infections ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Claims database ,Omeprazole ,Helicobacter pylori ,biology ,business.industry ,Pharmacoepidemiology ,biology.organism_classification ,3. Good health ,Metronidazole ,Treatment Outcome ,surgical procedures, operative ,Drug Therapy, Combination ,business ,Bismuth ,Cohort study ,medicine.drug - Abstract
Summary Background Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in France after 40 years. Objective To describe the real-life patterns of use of BMT following a request from the French health authorities. Methods Patients with a first BMT dispensing (index date, ID), with one year of data before and after ID, were identified in the French nationwide claims database 1/97 sample. Misuse of BMT was defined as dispensing >1 pack of BMT at ID or absence of a diagnostic test in the preceding year. Results In total, 540 patients were included. Prescribers were gastroenterologists (n = 243; 45%) and general practitioners (n = 160; 30%). A proton pump inhibitor was co-dispensed to 504 patients (96%). Ten patients (2%) had contraindications to BMT. Fifty-nine patients (11%) met the misuse criteria: ten (2%) were dispensed > 1 pack of BMT and 49 (9%) had not had a diagnostic test for H. pylori in the previous year. During follow-up, 27 patients (5%) required retreatment (treatment failure). Conclusion In this real-life study, most patients were dispensed only one pack of BMT, consistent with recommendations. Misuse related principally to the absence of prior diagnostic test for H. pylori.
- Published
- 2021